Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ImmuPharma ( (GB:IMM) ) has shared an update.
ImmuPharma PLC has appointed Ketan Patel as an independent Non-Executive Director to its Board. Patel brings extensive expertise in financial markets, particularly in the UK healthcare and life science sectors, which will aid ImmuPharma in forming strategic partnerships and expanding its institutional shareholder base. This appointment is expected to enhance the company’s strategic positioning and operational focus, especially concerning its lead auto-immune platform technology, P140.
More about ImmuPharma
ImmuPharma PLC is a specialty biopharmaceutical company focused on discovering and developing peptide-based therapeutics. The company’s portfolio includes novel peptide therapeutics aimed at treating autoimmune diseases and anti-infectives.
Average Trading Volume: 11,445,443
Technical Sentiment Signal: Buy
Current Market Cap: £55.8M
Find detailed analytics on IMM stock on TipRanks’ Stock Analysis page.